Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression? Evidence From Selective Neurotransmitter Depletion Studies.

Next Previous
Trial Profile

What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression? Evidence From Selective Neurotransmitter Depletion Studies.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar disorders
  • Focus Pharmacodynamics

Most Recent Events

  • 07 Jul 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
  • 10 Apr 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
  • 19 Sep 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top